Anxiety Disorder Treatment Market Research Report - Global Forecast till 2025

Global Anxiety Disorder Treatment Market Research Report: By Drug Class (SSRIs, SNRIs, TCAs, Pregabalin, Buspirone, Benzodiazepines, Moclobemide, Others) and By End-User (Hospitals, Mental Healthcare Centers, Asylums, Others) – Forecast to 2025

ID: MRFR/HC/6983-HCR | February 2021 | Region: Global | 100 pages

Market Forecast


Anxiety Disorder Treatment Market is expected to reach USD 11.54 million in 2018 at a CAGR of 5.4%.


Market Synopsis


Mental illness accounts for 12 % of the burden of disease worldwide. Anxiety disorders include obsessive-compulsive disorder, phobias, post-traumatic stress disorder (PTSD), and panic disorder. Anxiety disorders are the most prevalent psychiatric disorders and are associated with a high burden of illness. This raises the need for the development of innovative drugs for the treatment of anxiety disorders.


Moreover, the presence of favorable reimbursement policies in developed regions for medications and therapies are positively influencing the market growth. This is positively impacting the demand for anxiety disorder treatment. Along with drugs and cognitive-behavioral therapies, support and education play an essential role for better community understanding for the treatment of anxiety disorders.


Market Influencer


Rising prevalence of anxiety disorders has increased the demand for effective treatment options.


Market Drivers




  • Rising incidences of anxiety disorders (social anxiety disorder, generalized anxiety disorder, agoraphobia, and others). For instance, anxiety disorders are the most common mental illness in the US, affecting 40 million adults aged 18 and above. The demand for effective anxiety disorder treatment is driven by the rising need for managing such a chronic disease.




  • Presence of favorable reimbursement policies in developed countries




  • Increasing geriatric population and change in lifestyle among people. Currently, 14.5% of the US population is age 65 and above. The incidences of anxiety disorders are continuously rising in the geriatric population. This population is prone to psychological diseases, thus contributing significantly to the growth of this market.




  • Introduction of technologically advanced therapies




Market Restraints



  • Patent expiration of branded medicines

  • Introduction of generic biosimilars. Biosimilars are highly similar versions of approved biologics that have reached the end of their proprietary patents. The introduction of generic biosimilars by critical players as a cost-effective alternative is expected to hamper the growth of this market.


Segmentation


By Drug Class




  • SSRIs (Selective Serotonin Reuptake Inhibitors): SSRIs are a class of drugs that are typically used as antidepressants. They are majorly used in the treatment of anxiety disorders and depressive disorders. They exhibit fewer side-effects than other antidepressants. SSRIs drugs relieve symptoms of depressive disorders by blocking the reabsorption of serotonin through specific nerve cells situated in the brain.




  • SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors): SNRIs are used to relieve the symptoms of anxiety disorders, nerve pain, and depression symptoms, such as irritability and sadness.




  • TCAs (Tricyclic Antidepressants): Tricyclic antidepressants affect brain chemicals to ease depression symptoms.




  • Pregabalin: Pregabalin is used to treat generalized anxiety disorder and epilepsy. Pregabalin also affects chemicals in the brain that send pain signals across the nervous system.




  • Buspirone: Buspirone is primarily used in the treatment of anxiety disorder, particularly generalized anxiety disorder. Buspirone is in a class of medications called anxiolytics.




  • Benzodiazepines: Benzodiazepines are a class of drugs primarily used for treating anxiety.




  • Moclobemide: Moclobemide is a medication used to treat depression and social anxiety. It is not approved for use in the US but is supported in other Western countries such as Canada, the UK, and Australia.




  • Others




By End-User



  • Hospitals: The largest segment, an increasing number of patients, and the growing financing capabilities of healthcare settings are responsible for the growth of the segment. The ever-increasing number of hospitals in different regions of world and government initiatives to improve the healthcare sector is anticipated to propel the growth of this segment.

  • Mental Healthcare Centers: Mental Healthcare Centers offer the most extensive care, along with the primary line of treatment.

  • Asylums: Asylums are the first institutions created for the specific purpose of housing people with a psychological disorder.

  • Others


By Region




  • Americas: The largest regional market. The increase in the incidence rate of anxiety disorder will boost market growth in this region. The sedentary lifestyle and stressful work environments are the major factors responsible for the rising cases of anxiety disorders in the US.




  • Europe: An increasing public awareness about anxiety disorders is leading to a rise in the demand for effective treatments of anxiety disorders.




  • Asia-Pacific: The fastest-growing regional market, Asia-Pacific is seeing a surge in the number of anxiety disorders such as generalized anxiety disorder. This rising prevalence of psychological diseases is increasing the demand for effective therapy to treat anxiety disorders. Such factors will boost the adoption of anxiety disorder treatment. The growth potential in the emerging economies of Asia-Pacific is expected to provide numerous opportunities for market expansion during the forecast period.




  • Middle East & Africa: The smallest market due to limited healthcare infrastructure and lack of awareness about anxiety disorder treatment in this region.




Key Players



  • Eli Lilly and Company (US)

  • Forest Laboratories, Inc. (US)

  • AstraZeneca PLC (UK)

  • Sanofi-Aventis (France)

  • Merck & Co., Inc. (US)

  • Pfizer, Inc. (US)

  • GlaxoSmithKline PLC (UK)

  • Johnson & Johnson (US)

  • Lundbeck A/S (Denmark)

  • Bristol-Myers Squibb Company (US)



Frequently Asked Questions (FAQ) :


The valuation of the global anxiety disorder treatment market had reached USD 11.54 MN in 2018.

The global anxiety disorder treatment market is projected to grow at approximately 5.4% CAGR during the forecast period (2019-2025).

Presence of favorable reimbursement policies in developed countries.

North America holds the largest share in the global anxiety disorder treatment market, followed by Europe and the Asia Pacific, respectively.

Forest Laboratories, Inc. (US), Eli Lilly and Company (US), AstraZeneca PLC (UK), Merck & Co., Inc. (US), Sanofi-Aventis (France), Pfizer, Inc. (US), Johnson & Johnson (US), GlaxoSmithKline PLC (UK), Lundbeck A/S (Denmark), and Bristol-Myers Squibb Company (US), are some of the major players operating in the anxiety disorder treatment market.



This table of content is tentative and subject to change as the research progresses.

Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.